Subscribe to RSS
DOI: 10.1055/s-0044-101461
Langzeitergebnisse nach Trabekulektomie kombiniert mit Mitomycin C und einem Ologen-Implantat
Long-Term Results after Trabeculectomy Combined with Mitomycin C and Ologen ImplantPublication History
eingereicht 02 August 2017
akzeptiert 08 January 2018
Publication Date:
28 March 2018 (online)
![](https://www.thieme-connect.de/media/klimo/201909/lookinside/thumbnails/10-1055-s-0044-101461_kl1830-1.jpg)
Zusammenfassung
Hintergrund Das Ologen-Implantat (AeonAstron Europe B. V., Leiden, Niederlande) besteht aus einem biodegradierbaren Kollagen und Glycosaminoglykan und soll eine postoperative Filterkissenvernarbung oder Abkapselung vermeiden.
Methodik In einer retrospektiven klinischen Studie wurden 806 Patienten mit fortgeschrittenem Glaukombefund mit einer Trabekulektomie kombiniert mit Mitomycin C0,02% und einem Ologen-Implantat behandelt. Die Follow-up-Zeit der Studie betrug 8 Jahre.
Ergebnisse Bei 92,6% der Patienten wurde in der Beobachtungszeit eine dauerhafte Drucksenkung von < 16 mmHg ohne das erneute Ansetzen einer drucksenkenden Therapie erreicht. Bei 6,8% der Patienten erfolgten zusätzliche operative Eingriffe bei Überfiltration oder Hypotonie mit Aderhautamotio. Bei der kombinierten Operation mit Phakoemulsifikation und Implantation einer Hinterkammerlinse kam es bei 3,35% der Patienten zur Revision des Filterkissens oder einem erneuten drucksenkenden Eingriff innerhalb von 8 Jahren.
Schlussfolgerung Eine Trabekulektomie kombiniert mit Mitomycin C0,02% und einem Ologen-Implantat schafft einen langfristigen filtrierenden Effekt < 16 mmHg und eine verringerte postoperative Komplikationsrate.
Abstract
Background The Ologen implant consists of a biodegradable collagen and glycosaminoglycan and is intended to avoid postoperative bleb scarring or encapsulation.
Materials and Methods In a retrospective clinical study, 806 patients with advanced glaucoma were treated with trabeculectomy combined with mitomycin C0.02% and Ologen implant. The follow-up time of the study was 8 years.
Results A long-term reduction of the intraocular pressure below 16 mmHg was achieved in 92.6% of the patients without glaucoma eye drops in the long-term observation period. The rate of complication was very low during the postoperative period and additional surgical procedures for over-filtration with subsequent choroidal detachment were seen in 6.8% of the patients. A failure of the combined operation with phacoemulsification and implantation of an intraocular lens resulted in revision of the bleb or the application of compressive sutures in 3.35% of patients within 8 years.
Conclusion The Ologen implant was introduced in glaucoma surgery to increase the effectiveness of trabeculectomy and to reduce the complications. Trabeculectomy combined with mitomycin C0.02% and an Ologen implant provides a satisfactory filtering effect without the undesirable effects of postoperative fibrosis.
-
Literatur
- 1 Dietlein TS, Jordan J, Lueke C. et al. Modern concepts in antiglaucomatous implant surgery. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1653-1664
- 2 Jordan JF. Modulation der Wundheilung in der filtrierenden Glaukomchirurgie. Ophthalmologe 2003; 100: 340-359
- 3 Papaconstantinou D, Georgalas I, Karmiris E. et al. Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol 2010; 88: 80-85
- 4 Rao K, Ahmed I, Blake DA. et al. New devices in glaucoma surgery. Expert Rev Ophthalmol 2009; 4: 491-504
- 5 Picht G, Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol 1998; 9: 2-8
- 6 Rosentreter A, Schild AM, Jordan JF. et al. A prospective randomised trial of trabeculectomy using mitomycin C vs. an ologen implant in open angle glaucoma. Eye (Lond) 2010; 24: 1449-1457
- 7 Narayanaswamy A, Perera SA, Htoon HM. et al. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Clin Exp Ophthalmol 2013; 41: 552-560
- 8 Hsu W, Spilker MH, Yannas IV. et al. Inhibition of conjunctival scarring and contraction by a porous collagen glycosaminoglycan implant. Invest Ophthalmol Vis Sci 2000; 41: 2404-2411
- 9 Chen HS, Ritch R, Krupin T. et al. Control of filtering bleb structure through tissue bioengineering. An animal model. Invest Ophthalmol Vis Sci 2006; 47: 5310-5314
- 10 Hsu WC, Ritch R, Krupin T. et al. Tissue bioengineering for surgical bleb defects: an animal study. Graefes Arch Clin Exp Ophthalmol 2008; 246: 709-717
- 11 Chen HS, Hsu WC. Initial clinical experience with biodegradable 3D porous collagen-glycosaminoglycan scaffold (OculusGen) for treatment of refractory glaucoma. Presented at: World Ophthalmology Congress. Sao Paulo, Brazil, 1 – 24 February 2006.
- 12 Rosentreter A, Mellein AC, Konen WW. et al. Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1319-1324
- 13 Boey PY, Narayanaswamy A, Zheng C. et al. Imaging of blebs after phacotrabeculectomy with Ologen collagen matrix implants. Br J Ophthalmol 2011; 119: 314-320
- 14 Sarkisian SR. A replacement for antimetabolites? Ologen is a new product that modulates wound healing in glaucoma surgery. Glaucoma Today 2010; 8: 22-24
- 15 Zelefsky JR, Hsu WC, Ritch R. Biodegradable collagen matrix implant for trabeculectomy. Expert Rev Ophthalmol 2008; 3: 613-617
- 16 Aptel F, Dumas S, Denis P. Ultrasound biomicroscopy and optical coherence tomography imaging of filtering blebs after deep sclerectomy with new collagen implant. Eur J Ophthalmol 2009; 19: 223-230
- 17 Nilforushan N, Yadegari M, Hodjat P. Comparison of the success rate of trabeculectomy with OculusGen versus trabeculectomy with mitomycin C. Iran J Ophthalmol 2011; 23: 3-12
- 18 Stalmans I, Gillis A, Lafout AS. et al. Safe trabeculectomy technique: long term outcome. Br J Ophthalmol 2006; 90: 44-47
- 19 Senthil S, Rao HL, Babu JG. et al. Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma. Indian J Ophthalmol 2013; 61: 338-342
- 20 Aeon Astron Europe B V. About ologen® Collagen Matrix. Im Internet: http://www.aeonastron.com/product.php?catId=6 Stand: 12.10.2017